Photo from wikipedia
This study (https://doi.org/10.1245/s10434-022-11577-2) included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM), treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020.… Click to show full abstract
This study (https://doi.org/10.1245/s10434-022-11577-2) included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM), treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox ? 5-FU/L group) and patients who did not (PIPAC-Ox group). The safety and feasibility of PIPAC-Ox ? 5-FU/L appear to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.
Journal Title: Annals of Surgical Oncology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!